Media With Mental Health to Work Together for Suicide Prevention???


suicide stats

Public health burden of suicidal behavior among adults

aged =18 years — United States, 2008

The Deseret News in Salt Lake City just ran an article titled, “Media, mental health professionals discuss working together on suicide prevention?” Really? And how many are going to fall for that? The link to this original article is below and here is my comment on that article:

“Without question suicide is a huge problem plaguing our society. But in searching the cause few see the obvious as the cause, even when admitted, due to the huge amount of revenue associated with it. That is the drugs prescribed to those who are depressed – antidepressants which carry warnings of suicidal ideation. A decade ago antidepressants were given an FDA Black Box Warning (the next step from a complete ban).

“Now we should feel better knowing that media, who receive massive amounts of advertising dollars to promote these drugs, and groups like NAMI, who was shown by a Senate Probe led by Senator Charles Grassley to be 75% funded by Pharma, are looking for answers? Also just days ago JAMA published a study showing 40% of teaching hospitals, like UNI, have drug company ties.

“Propublica in their Dollars for Docs program is working to stop these vested interests. Until it is no longer financially advantageous to those searching I would not expect real answers to suicide prevention. The answer will continue to be “Take your drugs and don’t worry about the suicidal ideation warning. It will not affect you, only others.”

I should have finished with this line, “It will not affect you, only others, because as soon as you go manic on your antidepressant you will become invincable.”

Original Article:

Ann Blake Tracy, Executive Director,
International Coalition for Drug Awareness &
Author: ”Prozac: Panacea or Pandora? – Our Serotonin Nightmare – The Complete Truth of the Full Impact of Antidepressants Upon Us & Our World” & Withdrawal CD “Help! I Can’t Get Off My Antidepressant!”

WITHDRAWAL HELP: You can find the hour and a half long CD on safe and effective withdrawal helps here:  And if you need additional consultations with Ann Blake-Tracy, you can book one at or sign up for one of the memberships for the International Coalition for Drug Awareness which includes free consultations as one of the benefits of that particular membership plan.

WITHDRAWAL WARNING: In sharing this information about adverse reactions to antidepressants I always recommend that you also give reference to my CD on safe withdrawal, Help! I Can’t Get Off My Antidepressant!, so that we do not have more people dropping off these drugs too quickly – a move which I have warned from the beginning can be even more dangerous than staying on the drugs!

The FDA also now warns that any abrupt change in dose of an antidepressant can produce suicide, hostility or psychosis. These reactions can either come on very rapidly or even be delayed for months depending upon the adverse effects upon sleep patterns when the withdrawal is rapid!

JAMA: Mild to severe depression better treated with alternatives to medications

Last month, a team at the University of Pennsylvania found only patients
with very severe depression were measurably helped by antidepressant drugs. Mild
to severe depression might be better treated with alternatives to antidepressant
drugs, they wrote in the Journal of the American Medical Association.

To: ,,,
Sent: 2/14/2010 8:12:09 A.M. Central Standard
Subj: Even when treated, depression costs employers

when treated, depression costs employers
Tue, 09 Feb 20:05 PM

WASHINGTON (Reuters) – Workers with depression stay home
sick more often than healthy colleagues, even when their disease is treated,
according to a Thomson Reuters report released on Tuesday.

The report,
commissioned by drug maker Sanofi Aventis, suggests that employers would
benefit from better treatments of their workers for depression. Depression is
the leading cause of disability among Americans aged 15 to 44, according to
the National Institute of Mental Health.

“Even when depressed patients
are treated with antidepressants, there are substantial productivity losses.
Therapies that can better manage depression may provide opportunities for
savings to employers,” the Thomson Reuters research team wrote in the Journal
of Occupational and Environmental Medicine.

“Despite the widely
acknowledged effectiveness of antidepressant therapy, productivity costs
related to depression persist even after patients receive treatment,” Suellen
Curkendall, director of outcomes research at Thomson Reuters, said in a

“This may be due to the fact that patients often don’t
respond to the first type of antidepressant that they are prescribed. They
also may fail to take their medications on a regular basis,” added Curkendall,
who led the study.

Curkendall and colleagues analyzed insurance claims
and employee health and productivity data for more than 22,000 patients
treated with antidepressants and compared them to people without

Workers who had been treated for depression were twice as
likely as others to use short-term disability leave, they found.
Disability-related costs for a year, on average, were $1,038 for patients
treated for depression and $325 for the non-depressed workers.

“Over 40
percent of patients with depression were diagnosed with at least one of the
other included psychiatric conditions besides depression,” the researchers at
Thomson Reuters, parent company of Reuters, added.

Most common were
anxiety, dissociative and so-called somatoform disorders — a group of
disorders with physical symptoms but no apparent physical cause.

month, a team at the University of Pennsylvania found only patients with very
severe depression were measurably helped by antidepressant drugs. Mild to
severe depression might be better treated with alternatives to antidepressant
drugs, they wrote in the Journal of the American Medical

At least 27 million Americans take antidepressants and
more than 164 million prescriptions for antidepressants were written in 2008,
totaling nearly $10 billion in U.S. sales and $20 billion globally, according
to IMS Health.

(Reporting by Maggie Fox, editing by Jackie
Sent via BlackBerry by

5/1/2002 • Timing of New Black Box Warnings and Withdrawals for Prescription Medications

5/1/2002 • Timing of New Black Box Warnings and Withdrawals for Prescription Medications

Karen E. Lasser, MD, MPH; Paul D. Allen, MD, MPH; Steffie J. Woolhandler, MD, MPH; David U. Himmelstein, MD; Sidney M. Wolfe, MD; David H. Bor, MD

Journal of the American Medical Association
JAMA. 2002;287:2215-2220

Serious ADRs commonly emerge after Food and Drug Administration approval. The safety of new agents cannot be known with certainty until a drug has been on the market for many years.



Diagnosis of Attention-Deficit/Hyperactivity Disorder and Use of
Psychotropic Medication in Very Young Children

Marsha D. Rappley, MD; Patricia B. Mullan, PhD; Francisco J. Alvarez;
Ihouma U. Eneli, MD; Jenny Wang, PhD; Joseph C. Gardiner, PhD


Children aged 3 years or younger had ADHD diagnosed and received
markedly variable psychotropic medication regimens. Little information
is available to guide these practices. The presence of comorbid
conditions and injuries attests to these children’s vulnerability.
Resources must be identified that will enable physicians to better
respond to the compelling needs of these children and their families.

Editor’s Note: The authors point out a pressing need to define better
diagnostic criteria and effective treatment in very young children.
There seems to be a real deficit in attention to this
problem.—Catherine D. DeAngelis, MD